|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. CS-GAGs are required for proliferation of neural precursor cells during
forebrain development. (A,B) Photomicrographs of
immunohistochemical stainings of E14.5 mouse forebrain cryosections 1 day
after ventricular injection with ACSF control (upper panels) or ChABC (lower
panels). Cell nuclei were counterstained with bisbenzimide and are shown in
blue (DAPI). (A) The dividing progenitors were identified by PH3
immunoreactivity. Note that ChABC treatment caused a significant reduction in
the number of neural precursor cells undergoing mitosis. (B) The actively
cycling cell population was labeled with BrdU. Note that ChABC treatment
caused a significant reduction in the number of neural precursor cells
undergoing S phase. (C) Quantification of the total number of
PH3-positive cells in selected cortical and striatal (GE) areas revealed a
significant reduction in the ChABC-injected (light gray) in comparison with
the control-injected (dark gray) embryos (upper panel). ChABC treatment also
altered the distribution of the neural precursor cells (lower panel). Note
that significantly more cells were in M phase at the ventricular surface in
control-injected brains. (D) Quantification of the total number of
BrdU-positive cells in defined cortical and striatal (GE) areas revealed a
significant reduction in the ChABC-injected (light gray) in comparison with
the control-injected (dark gray) embryos (upper panel). Note that in
ChABC-injected forebrains, more BrdU-positive cells were located in layers of
the VZ/SVZ more distant to the ventricular surface (lower panels). Cor,
cortex; ge, ganglionic eminence; lv, lateral ventricle. *,
P<0.05; **, P<0.01; ***,
P<0.001. Scale bars: 100 µm.
|
